GlassScriptPhysician profile
Christopher P Lopez
NPI 1992702716
$16,441.28
in general payments reported to CMS, 2019-2025
57 companies · $2,230 in 2025
The $2,230 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,020 · 2020: $2,123 · 2021: $3,392 · 2022: $1,820 · 2023: $2,270 · 2024: $2,586 · 2025: $2,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,086.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,309.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,319.79 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,085.53 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,062.89 | 2019-2025 | |
| Novo Nordisk INC | $946.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $887.97 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $875.23 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $850.84 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $756.99 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $510.50 | 2019-2025 | |
| Lilly USA, LLC | $482.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $428.18 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $376.50 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $334.02 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.93 | 2019-2025 | Xifaxan |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $292.12 | 2019-2025 | Eliquis |
| Allergan, INC. | $232.35 | 2019-2020 | |
| Amarin Pharma, INC. | $227.00 | 2019-2021 | |
| Abbott Laboratories | $221.58 | 2022-2025 | Freestyle Libre, Freestyle Libre 3 |
| Exact Sciences Corporation | $215.01 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Phathom Pharmaceuticals, INC. | $200.99 | 2023-2025 | Voquezna |
| Daiichi Sankyo INC. | $194.66 | 2019-2024 | Injectafer |
| Astellas Pharma US INC | $187.33 | 2019-2023 | Veozah |
| Lundbeck LLC | $172.38 | 2024-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $159.66 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.47 | 2020-2024 | Livtencity |
| Kowa Pharmaceuticals America, INC. | $128.73 | 2019-2023 | Livalo, Seglentis |
| Sumitomo Pharma America, INC. | $113.88 | 2023-2024 | Gemtesa |
| Eisai INC. | $108.75 | 2020-2022 | |
| Tolmar, INC. | $106.15 | 2023-2025 | Jatenzo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.21 | 2022 | |
| Antares Pharma, INC. | $97.61 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Dexcom, INC. | $92.08 | 2021-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $88.98 | 2021-2024 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $78.53 | 2023-2025 | Rexulti |
| Mannkind Corporation | $71.35 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $69.96 | 2023-2024 | Aveed |
| Idorsia Pharmaceuticals US INC | $67.06 | 2023-2024 | Quviviq |
| Biogen, INC. | $58.58 | 2025 | Skyclarys |
| Supernus Pharmaceuticals, INC. | $56.92 | 2020-2022 | Xyosted, Tlando |
| Teva Pharmaceuticals USA, INC. | $53.54 | 2020-2022 | |
| Paratek Pharmaceuticals, INC. | $47.26 | 2021-2023 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $43.14 | 2021-2022 | |
| Halozyme INC | $37.98 | 2023 | |
| Ibsa Pharma INC. | $34.99 | 2020 | |
| Aimmune Therapeutics, INC. | $25.00 | 2025 | Zenpep |
| Abiomed | $22.99 | 2024 | Impella |
| Melinta Therapeutics, LLC | $21.72 | 2023 | Orbactiv, Kimyrsa, Vabomere |
| Clarus Therapeutics INC. | $20.80 | 2021 | |
| Kyowa Kirin, INC. | $20.74 | 2023 | Crysvita |
| Mylan Specialty L.P. | $18.35 | 2020 | |
| Sanofi Pasteur INC. | $18.21 | 2019 | |
| Averitas Pharma INC. | $18.05 | 2023 | Qutenza |
| Arbor Pharmaceuticals, INC. | $17.77 | 2019 | |
| Adlon Therapeutics L.P. | $14.46 | 2020 | |
| Axsome Therapeutics, INC. | $13.11 | 2023 | Sunosi |
| Amneal Pharmaceuticals LLC | $12.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lopez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.